Healthcare Distribution Alliance – Patients Move Us.
Share Print
blog banner

HDA Blog

Blog Entries

Davis Spotlights HDA's 2021 Strategic Priorities

Posted

HDA will be carrying forward the early lessons learned from COVID-19 pandemic and supporting response efforts in 2021, writes President and CEO Chip Davis in the January 4 issue of Chain Drug Review — particularly as distributors play a role in the largest public vaccination effort in recent memory. Davis provided his perspective on the year ahead, along with other healthcare trade association leaders, as part of the publication’s 2021 “Pharmacy Outlook” feature.

Read more...

DSCSA, the 2023 Requirements and EPCIS

Posted by Anita T. Ducca

Since the enactment of the Drug Supply Chain Security Act in 2013, members of the pharmaceutical supply chain have undertaken efforts to meet each of the major milestones contained within the statute’s 10-year timeline to further secure the safety of the products being distributed. The industry’s progress to 2023 interoperability was top of mind as supply chain and other stakeholders came together at HDA’s recent Traceability Online Seminar.

Read more...

HDA Highlights Distributors' Value, 2020 Policy Outlook in Chain Drug Review

Posted

With 2020 underway, HDA’s John M. Gray provided perspective on the vital role of pharmaceutical distributors and the Alliance’s policy priorities as part of Chain Drug Review’s annual “Pharmacy Outlook” feature.

Read more...

DSCSA Saleable Returns: Industry Plan for Best Using the Enforcement Discretion Period

Posted by Justine Freisleben

It has been clear for some time that the pharmaceutical supply chain has been concerned with meeting the November 27, 2019, saleable returns milestone. As the HDA’s Research Foundation’s annual Serialization Readiness Survey (conducted in May) notes, 79 percent of manufacturers have concerns with the viability of the Verification Router Service (VRS), while 82 percent of distributors are unsure about meeting the requirement.

Read more...

HDA Featured in Chain Drug Review's 2019 "Pharmacy Outlook"

Posted

With a new year in full swing, HDA President and CEO John M. Gray looked ahead to the organization’s 2019 priorities (along with other industry association executives) as part of the Chain Drug Review “Pharmacy Outlook” feature.

Read more...
View more
© 2020 Healthcare Distribution Alliance. All rights reserved.
HDA: E | C | C2 | NF | O365